Research Article

Effect of Statins on Major Adverse Cardiovascular Events in Patients with Coronary Artery Spasm: A Meta-Analysis of the Asia Region

Table 1

Main characteristics of included studies (statin group vs. no-statin group, number (%)).

StudyHypertensionDiabetes mellitusDyslipidemiaSmokingAspirinCCBNitrateNicorandilβ-BlockersACEIs/ARBs

Kensuke Io et al.NR
Sunao Kodama et al.NR
Munenori Kosugi et al.NR
Akihiro Nakagomi et al.NR
Masanobu Ishii et al.60 (46.9) vs. 53 (41.4)26 (20.3) vs. 21 (16.7)121 (94.5) vs. 50 (39.1)50 (39.1) vs. 51 (39.8)37 (28.9) vs. 35 (27.3)122 (95.3) vs. 124 (96.9)14 (10.9) vs. 19 (14.8)9 (7.0) vs. 9 (7.0)8 (6.3) vs. 6 (4.7)34 (26.6) vs. 29 (22.7)
Min Seok Oh et al.110 (39.1) vs. 111 (39.5)71 (25.4) vs. 73 (26.0)NR89 (31.7) vs. 82 (29.2)180 (64.1) vs. 179 (63.7)274 (97.5) vs. 274 (97.5)108 (38.4) vs. 105 (37.4)102 (36.3) vs. 97 (34.5)NR50 (17.8) vs. 49 (17.4)
Zhe Hao Piao et al.122 (41.9) vs. 74 (35.6)34 (11.7) vs. 21 (10.1)29 (10.0) vs. 11 (5.3)156 (53.8) vs. 115 (55.3)229 (80.4) vs. 121 (72.0)245 (83.9) vs. 169 (80.9)191 (65.6) vs. 116 (59.2)99 (35.0) vs. 66 (33.7)41 (14.0) vs. 17 (8.1)139 (47.6) vs. 83 (39.7)
So Jin Park et al.1265 (54.9) vs. 869 (48.4)879 (38.2) vs. 617 (34.4)NRNR2177 (94.5) vs. 1528 (85.1)1973 (85.6) vs. 1476 (82.2)2072 (89.9) vs. 1547 (86.2)1108 (48.1) vs. 740 (41.2)NR895 (38.8) vs. 474 (26.4)
Won-Woo Seo et al.306 (41.1) vs. 296 (32.4)73 (9.8) vs. 70 (7.7)276 (37.1) vs. 125 (13.7)NR394 (53.0) vs. 239 (26.1)701 (94.2) vs. 791 (86.5)614 (82.5) vs. 726 (79.4)NR46 (6.2) vs. 59 (6.5)168 (22.6) vs. 98 (10.7)
Hiroyoshi Mori et al.101 (47.9) vs. 101 (47.9)38 (18.0) vs. 32 (15.2)136 (64.5) vs. 137 (64.9)134 (63.5) vs. 122 (57.8)112 (53.1) vs. 108 (51.2)197 (93.4) vs. 203 (96.2)99 (46.9) vs. 92 (43.6)NR7 (3.3) vs. 9 (4.3)45 (21.3) vs. 57 (27.0)

NR: not reported; CCB: calcium-channel blocker; ACEIs/ARBs: angiotensin-converting enzyme inhibitors/angiotensin receptor blockers.